The Braf kinase inhibitors market is driven by increasing prevalence of various cancers globally. For instance, according to WHO estimates, cancer burden is expected to grow to 27.5 million new cases and 16.3 million cancer deaths by 2040. Additionally, approval and launch of new products is also expected to fuel market growth over the forecast period. For example, in July 2018, Pfizer...
Arabic
Français
Español
Português
Deutsch
Türkçe
Dutch
Italiano
Russian
Romaian